151 related articles for article (PubMed ID: 23538183)
1. Cost-effectiveness of a program to eliminate disparities in pneumococcal vaccination rates in elderly minority populations: an exploratory analysis.
Michaelidis CI; Zimmerman RK; Nowalk MP; Smith KJ
Value Health; 2013; 16(2):311-7. PubMed ID: 23538183
[TBL] [Abstract][Full Text] [Related]
2. Estimating the cost-effectiveness of a national program to eliminate disparities in influenza vaccination rates among elderly minority groups.
Michaelidis CI; Zimmerman RK; Nowalk MP; Smith KJ
Vaccine; 2011 Apr; 29(19):3525-30. PubMed ID: 21406266
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of programs to eliminate disparities in elderly vaccination rates in the United States.
Michaelidis CI; Zimmerman RK; Nowalk MP; Smith KJ
BMC Public Health; 2014 Jul; 14():718. PubMed ID: 25023889
[TBL] [Abstract][Full Text] [Related]
4. Pneumococcal Vaccination Strategies in 50-Year-Olds to Decrease Racial Disparities: A US Societal Perspective Cost-Effectiveness Analysis.
Altawalbeh SM; Wateska AR; Nowalk MP; Lin CJ; Harrison LH; Schaffner W; Zimmerman RK; Smith KJ
Value Health; 2024 Jun; 27(6):721-729. PubMed ID: 38462225
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race.
Sisk JE; Whang W; Butler JC; Sneller VP; Whitney CG
Ann Intern Med; 2003 Jun; 138(12):960-8. PubMed ID: 12809452
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of pneumococcal and influenza vaccination standing order programs.
Lin CJ; Zimmerman RK; Smith KJ
Am J Manag Care; 2013 Jan; 19(1):e30-7. PubMed ID: 23379777
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
[TBL] [Abstract][Full Text] [Related]
8. Economic evaluation of standing order programs for pneumococcal vaccination of hospitalized elderly patients.
Middleton DB; Lin CJ; Smith KJ; Zimmerman RK; Nowalk MP; Roberts MS; Fox DE
Infect Control Hosp Epidemiol; 2008 May; 29(5):385-94. PubMed ID: 18521990
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13) in older Australians.
Dirmesropian S; Wood JG; MacIntyre CR; Beutels P; McIntyre P; Menzies R; Reyes JF; Chen C; Newall AT
Vaccine; 2017 Aug; 35(34):4307-4314. PubMed ID: 28693751
[TBL] [Abstract][Full Text] [Related]
10. Pneumococcal Vaccination in Adults Aged ≥65 Years: Cost-Effectiveness and Health Impact in U.S. Populations.
Wateska AR; Nowalk MP; Lin CJ; Harrison LH; Schaffner W; Zimmerman RK; Smith KJ
Am J Prev Med; 2020 Apr; 58(4):487-495. PubMed ID: 32001052
[TBL] [Abstract][Full Text] [Related]
11. Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany.
Kuhlmann A; von der Schulenburg JG
Eur J Health Econ; 2017 Apr; 18(3):273-292. PubMed ID: 26905404
[TBL] [Abstract][Full Text] [Related]
12. [Economic evaluation of an infant immunization program in Mexico, based on 13-valent pneumococcal conjugated vaccines].
Muciño-Ortega E; Mould-Quevedo JF; Farkouh R; Strutton D
Value Health; 2011; 14(5 Suppl 1):S65-70. PubMed ID: 21839902
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.
Vučina VV; Filipović SK; Kožnjak N; Stamenić V; Clark AD; Mounaud B; Blau J; Hoestlandt C; Kaić B
Vaccine; 2015 May; 33 Suppl 1():A209-18. PubMed ID: 25919163
[TBL] [Abstract][Full Text] [Related]
14. The cost-effectiveness of using pneumococcal conjugate vaccine (PCV13) versus pneumococcal polysaccharide vaccine (PPSV23), in South African adults.
Feldman C; Dlamini SK; Madhi SA; Meiring S; von Gottberg A; de Beer JC; de Necker M; Stander MP
PLoS One; 2020; 15(1):e0227945. PubMed ID: 31995597
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness of the 4 Pillars Practice Transformation Program to Improve Vaccination of Adults Aged 65 and Older.
Smith KJ; Zimmerman RK; Nowalk MP; Lin CJ
J Am Geriatr Soc; 2017 Apr; 65(4):763-768. PubMed ID: 28024090
[TBL] [Abstract][Full Text] [Related]
16. An updated cost-effectiveness analysis of pneumococcal conjugate vaccine among children in Thailand.
Dilokthornsakul P; Kengkla K; Saokaew S; Permsuwan U; Techasaensiri C; Chotpitayasunondh T; Chaiyakunapruk N
Vaccine; 2019 Jul; 37(32):4551-4560. PubMed ID: 31280944
[TBL] [Abstract][Full Text] [Related]
17. Economic evaluation of childhood 7-valent pneumococcal conjugate vaccination in Korea.
Sohn HS; Suh DC; Jang E; Kwon JW
J Manag Care Pharm; 2010; 16(1):32-45. PubMed ID: 20044845
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of polysaccharide pneumococcal vaccination in people aged 65 and above in Poland.
Grzesiowski P; Aguiar-Ibáñez R; Kobryń A; Durand L; Puig PE
Hum Vaccin Immunother; 2012 Oct; 8(10):1382-94. PubMed ID: 23095867
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people.
Sisk JE; Moskowitz AJ; Whang W; Lin JD; Fedson DS; McBean AM; Plouffe JF; Cetron MS; Butler JC
JAMA; 1997 Oct 22-29; 278(16):1333-9. PubMed ID: 9343464
[TBL] [Abstract][Full Text] [Related]
20. Cost Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccination Program in Chronic Obstructive Pulmonary Disease Patients Aged 50+ Years in Spain.
Rodríguez González-Moro JM; Menéndez R; Campins M; Lwoff N; Oyagüez I; Echave M; Rejas J; Antoñanzas F
Clin Drug Investig; 2016 Jan; 36(1):41-53. PubMed ID: 26547199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
